Piramal Pharma [PPLPHARMA] vs Natco Pharma [NATCOPHARM] Detailed Stock Comparison

Piramal Pharma Ltd.

NSE
Loading...

Natco Pharma Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Piramal Pharma Ltd. wins in 3 metrics, Natco Pharma Ltd. wins in 16 metrics, with 0 ties. Natco Pharma Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Piramal Pharma Ltd. Natco Pharma Ltd. Better
P/E Ratio (TTM) 269.79 12.32 Natco Pharma Ltd.
Price-to-Book Ratio 2.47 2.22 Natco Pharma Ltd.
Debt-to-Equity Ratio 60.08 3.01 Natco Pharma Ltd.
PEG Ratio -0.38 0.89 Natco Pharma Ltd.
EV/EBITDA 25.20 9.10 Natco Pharma Ltd.
Profit Margin (TTM) -1.84% 34.13% Natco Pharma Ltd.
Operating Margin (TTM) -0.80% 17.38% Natco Pharma Ltd.
EBITDA Margin (TTM) N/A 17.38% N/A
Return on Equity 1.12% 24.77% Natco Pharma Ltd.
Return on Assets (TTM) 0.58% 21.85% Natco Pharma Ltd.
Free Cash Flow (TTM) $2.28B $11.85B Natco Pharma Ltd.
Dividend Yield 0.07% 0.73% Natco Pharma Ltd.
1-Year Return -18.17% -5.35% Natco Pharma Ltd.
Price-to-Sales Ratio (TTM) 2.25 4.21 Piramal Pharma Ltd.
Enterprise Value $240.47B $162.40B Piramal Pharma Ltd.
EV/Revenue Ratio 2.71 3.56 Piramal Pharma Ltd.
Gross Profit Margin (TTM) 63.25% 79.44% Natco Pharma Ltd.
Revenue per Share (TTM) $67 $255 Natco Pharma Ltd.
Earnings per Share (Diluted) $-1.23 $86.97 Natco Pharma Ltd.
Beta (Stock Volatility) 0.19 0.19 Natco Pharma Ltd.

Piramal Pharma Ltd. vs Natco Pharma Ltd. Stock Performance Analysis

Loading Price Chart...

PPLPHARMA
NATCOPHARM

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Piramal Pharma Ltd.2.04%1.12%-4.39%20.53%-2.62%-1.58%
Natco Pharma Ltd.-1.89%-2.38%-29.31%-10.42%-6.36%-4.57%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Piramal Pharma Ltd.-18.17%77.37%-2.17%-2.17%-2.17%-2.17%
Natco Pharma Ltd.-5.35%37.05%-21.16%69.86%1,522.04%4,430.15%

Performance & Financial Health Analysis: Piramal Pharma Ltd. vs Natco Pharma Ltd.

MetricPPLPHARMANATCOPHARM
Market Information
Market Cap i₹199.68B₹191.91B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i2,496,822701,464
90 Day Avg. Volume i3,143,094888,169
Last Close₹167.20₹847.60
52 Week Range₹132.30 - ₹220.85₹789.00 - ₹1,226.80
% from 52W High-24.29%-30.91%
All-Time High₹307.90 (Nov 04, 2024)₹1,639.00 (Sep 09, 2024)
% from All-Time High-45.70%-48.29%
Growth Metrics
Quarterly Revenue Growth-0.03%0.36%
Quarterly Earnings Growth-0.05%0.14%
Financial Health
Profit Margin (TTM) i-0.02%0.34%
Operating Margin (TTM) i-0.01%0.17%
Return on Equity (TTM) i0.01%0.25%
Debt to Equity (MRQ) i60.083.01
Cash & Liquidity
Book Value per Share (MRQ)₹61.03₹482.88
Cash per Share (MRQ)₹5.63₹178.93
Operating Cash Flow (TTM) i₹2.44B₹19.26B
Levered Free Cash Flow (TTM) i₹911.30M₹18.85B
Dividends
Last 12-Month Dividend Yield i0.07%0.73%
Last 12-Month Dividend i₹0.14₹6.50

Valuation & Enterprise Metrics Analysis: Piramal Pharma Ltd. vs Natco Pharma Ltd.

MetricPPLPHARMA (Apr 21, 2026)NATCOPHARM (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i269.7912.32
Forward P/E i67.2327.26
PEG Ratio i-0.380.89
Price to Sales (TTM) i2.254.21
Price to Book (MRQ) i2.472.22
Market Capitalization
Market Capitalization i₹199.68B₹191.91B
Enterprise Value i₹240.47B₹162.40B
Enterprise Value Metrics
Enterprise to Revenue i2.713.56
Enterprise to EBITDA i25.209.10
Risk & Other Metrics
Beta i0.190.19
Book Value per Share (MRQ) i₹61.03₹482.88

Financial Statements Comparison: Piramal Pharma Ltd. vs Natco Pharma Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricPPLPHARMA (2025)NATCOPHARM (2025)
Revenue/Sales i90.61B44.12B
Cost of Goods Sold i35.72B8.65B
COGS % of Revenue i39.4%19.6%
Gross Profit i54.89B35.46B
Gross Margin i60.6%80.4%
Research & Development i971.30M1.13B
Operating Income (EBIT) i6.79B19.81B
Operating Margin i7.5%44.9%
EBITDA i16.89B24.58B
EBITDA Margin i18.6%55.7%
Pre-Tax Income i4.15B22.91B
Pre-Tax Income % of Revenue i4.6%51.9%
Income Tax i3.24B4.08B
Income Tax % of Revenue i3.6%9.2%
Net Income (Profit) i911.30M18.83B
Profit Margin i1.0%42.7%

Balance Sheet & Liquidity Metrics

MetricPPLPHARMA (2025)NATCOPHARM (2025)
Cash & Equivalents i3.69B1.20B
Total Current Assets i57.97B52.70B
Total Current Assets % of Revenue i64.0%119.5%
Total Current Liabilities i37.66B9.44B
Total Current Liabilities % of Revenue i41.6%21.4%
Long-Term Debt i33.13B46.00M
Long-Term Debt % of Revenue i36.6%0.1%
Total Shareholders Equity i81.25B76.12B
Retained Earnings i10.49B62.47B
Retained Earnings % of Revenue i11.6%141.6%
Property, Plant & Equipment i250.60M474.00M

Cash Flow Statement Comparison

MetricPPLPHARMA (2025)NATCOPHARM (2025)
Operating Cash Flow i2.44B19.26B
Operating Cash Flow % of Revenue i2.7%43.7%
Capital Expenditures i-6.59B-3.06B
Free Cash Flow i2.28B11.85B
FCF Margin i2.5%26.9%
Debt Repayment i-10.65BN/A
Common Stock Repurchase iN/A0

Short Interest & Institutional Ownership Analysis

MetricPPLPHARMANATCOPHARM
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i1.32B179.11M
Float Shares i608.76M83.44M
% Held by Insiders i54.54%50.55%
% Held by Institutions i20.41%11.35%
% Held by Public i25.05%38.10%

Dividend Analysis & Yield Comparison: Piramal Pharma Ltd. vs Natco Pharma Ltd.

MetricPPLPHARMANATCOPHARM
Last 12-Month Dividend i₹0.14₹6.50
Last 12-Month Dividend Yield i0.07%0.73%
3-Year Avg Annual Dividend i₹0.08₹7.25
3-Year Avg Dividend Yield i0.07%0.24%
3-Year Total Dividends i₹0.25₹21.75
Ex-Dividend DateJul 16, 2025Feb 18, 2026